Nonsteroidal anti-inflammatory drugs (NSAIDs)- NSAIDs are the most effective therapy when initiated within 48 hours of the onset of gout symptoms. For initiation, the potent oral NSAIDs are Indomethacin (50 mg thrice daily) or Naproxen (500 mg twice daily). Other NSAIDs include Meloxicam (15 mg daily), Diclofenac (50 mg two to three times daily), Ibuprofen (800 mg thrice daily), and Celecoxib (200 mg twice daily). The NSAID treatment for gout flares typically lasts for five to seven days. NSAIDs are usually prescribed in full doses for the first three days. It is subsequently tapered based on the progress.

Febuxostat- Febuxostat is a selective xanthine oxidase inhibitor. It occupies the entry channel to the Molybdenum-Pterin active site of the enzyme. United States Food and Drug Administration (USFDA) has provided approval for Febuxostat to treat patients with gout and hyperuricaemia at a daily dosage of 40 mg, and if the urate levels do not normalise by two weeks, then the dosage is increased to 80 mg daily. Cardiovascular as well as hepatic abnormalities are reported with Febuxostat. In patients with chronic kidney disease, the urate-lowering effect of Febuxostat is considered to be superior to Allopurinol. Patients under the treatment of 6-Mercaptopurine (6-MP), Azathioprine, and Theophylline are considered to have contraindications to the use of Febuxostat.

Management of acute flares aims at reducing the inflammation and the resulting pain.

Nonsteroidal anti-inflammatory drugs (NSAIDs)- NSAIDs are the most effective therapy when initiated within 48 hours of the onset of gout symptoms. For initiation, the potent oral NSAIDs are Indomethacin (50 mg thrice daily) or Naproxen (500 mg twice daily). Other NSAIDs include Meloxicam (15 mg daily), Diclofenac (50 mg two to three times daily), Ibuprofen (800 mg thrice daily), and Celecoxib (200 mg twice daily). The NSAID treatment for gout flares typically lasts for five to seven days. NSAIDs are usually prescribed in full doses for the first three days. It is subsequently tapered based on the progress.

Febuxostat- Febuxostat is a selective xanthine oxidase inhibitor. It occupies the entry channel to the Molybdenum-Pterin active site of the enzyme. United States Food and Drug Administration (USFDA) has provided approval for Febuxostat to treat patients with gout and hyperuricaemia at a daily dosage of 40 mg, and if the urate levels do not normalise by two weeks, then the dosage is increased to 80 mg daily. Cardiovascular as well as hepatic abnormalities are reported with Febuxostat. In patients with chronic kidney disease, the urate-lowering effect of Febuxostat is considered to be superior to Allopurinol. Patients under the treatment of 6-Mercaptopurine (6-MP), Azathioprine, and Theophylline are considered to have contraindications to the use of Febuxostat.